The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and it's broken down into those three categories of you know monogenic highly penetrant I think the second category was it monogenic not highly penetrant or not monogenic I'd call it monogenic moderate risk modate penetrant and then polygenic
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
for the genes that I'll call monogenic highly penetrant let me unpack that a little bit monogenic good point monogenic single Gene highly penetrant high probability that over the life course you'll develop cancer if you have this particular Gene genetic variant so when you limit yourself to that yes about 5% of cancers are due to those powerful single genes
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.